Azacitidine

Also known as: Azacytidine

Therapeutic indications

Azacitidine is indicated for:

Irrespective of gender only Adults (18 years old or older)

Azacitidine is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder,
acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
AML with >30% marrow blasts according to the WHO classification.

For this indication, the medical literature mentions below treatments (click for details):

Active ingredient Azacitidine is contraindicated in the following cases:

It is unknown whether azacitidine/metabolites are excreted in human milk.

Due to the potential serious adverse reactions in the nursing child, breast-feeding is contraindicated during azacitidine therapy.